GLP-1 drugs are fueling the rise of the 'big kids' market, one mega restaurant chain says

Cava's CEO said weight-loss drugs are fuelling the rise of a "big kids" market. Dixie D. Vereen/For The Washington Post via Getty Images Diners on GLP-1 drugs are increasingly opting for kids' meals, said Cava CEO Brett Schulman. He called this group of consumers "big kids." GLP-1 drugs are known to suppress appetite and increase the need to consume more protein. Kids' meals are in vogue, according to Cava CEO Brett Schulman. The slop bowl chain is seeing an increasing consumer base that he...